News
News
Upcoming Events
Subscribe
Our Company
Our Story
Our Vision
Board of Directors
Alzinova Team
Advisers & Collaborators
R & D
Alzheimer's Disease
Our Programs
Specific Targeting of Toxic Aβ Oligomers
The AβCC Peptide™ Technology
Scientific Presentations
Patients & Families
Alzheimer's Patients
Impact on Society
The Unmet Medical Need
Investors
Overview
Analyses
Press Releases
English
Swedish
Subscribe
Presentations
Board and Management
The Share
Financial Reports
Financial Reports - English
Financial Reports – Swedish
Financial Calendar
Corporate Governance
General Meetings
IR Contact
Contact
Contact
Career
News
News
Upcoming Events
Subscribe
Our Company
Our Story
Our Vision
Board of Directors
Alzinova Team
Advisers & Collaborators
R & D
Alzheimer's Disease
Our Programs
Specific Targeting of Toxic Aβ Oligomers
The AβCC Peptide™ Technology
Scientific Presentations
Patients & Families
Alzheimer's Patients
Impact on Society
The Unmet Medical Need
Investors
Overview
Analyses
Press Releases
English
Swedish
Subscribe
Presentations
Board and Management
The Share
Financial Reports
Financial Reports - English
Financial Reports – Swedish
Financial Calendar
Corporate Governance
General Meetings
IR Contact
Contact
Contact
Career
Home
/
News
/
Alzinova takes the requirement for precision one step further
Alzinova takes the requirement for precision one step further
Date:
2026-04-24
Read the latest interview with our CEO Tord Labuda
Interview in Swedish
